Ann: Phosphagenics Arbitration Award Issued, page-164

It’s been a tough week for some Aussie biotechs and we’re only half way through the week…

Factor Therapeutics (FTT) has tumbled 97% to $0.002 - $0.003 this morning on the announcement of trial results for its candidate product for the adjunctive treatment of chronic venous leg ulcers. The Phase 2 trial commenced in 2016.

Unfortunately for both patients and FTT shareholders, no clinically meaningful or significant improvement was demonstrated on any primary or secondary endpoint.

Chris Behrenbruch stepped in as executive director in 2015 in a bid to transform the company because, he said, it had “fundamentally excellent technology”.

Commiserations to any holders.